FTSE 100 news / Companies and sectors / Pharma and healthcare / 16 October 2026
Pharma and healthcare: sector news on Friday 16 October 2026
Average tone +1.3 (neutral) across 5 companies with relevant coverage, from 65 stories.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +5.7 | 38 | Coverage was dominated by AstraZeneca's AI drug discovery partnership with insitro, worth up to about $1.5 billion and focused on MASH and cardiomyopathies. |
| GSK | +0.8 | 16 | Coverage was split between plans to cut up to 1,217 jobs in Belgium, with union blockades, and positive items such as an $800M US manufacturing hub, executive share purchases and a share price gain. |
| Smith & Nephew | +4.0 | 5 | Coverage was mainly about a 4.3% share price gain, the European launch of CARTIHEAL and an executive's comments on Latin America. |
| Haleon | −2.3 | 4 | Coverage was mixed, with an analyst downgrade and a trimmed UBS growth forecast weighing on sentiment. |
| Convatec | −1.8 | 2 | Coverage was light and mostly about the share price sitting well below a quoted target of 305.44p, plus a vague piece on a regulatory-news entry. |
Strongest stories in the sector
- +9.2 GSK Plans $800M Biopharma Manufacturing Hub in Pennsylvania
$800M US manufacturing investment shows expansion. - −8.3 Trade unions continue blocking GSK work sites following mass job cuts
Union blockades of work sites after mass job cuts. - +7.5 UBS Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $201.17
UBS maintains Buy rating with high target. - +7.5 RBC maintains 'outperform' on AstraZeneca, eyes strong lung cancer drug trial data
RBC keeps outperform, expects strong trial data. - +7.5 GSK shares gain almost 2% after CEO and CFO increase holdings and technical momentum builds
Shares up almost 2% after CEO and CFO buy. - +7.0 RBC keeps AstraZeneca at ‘outperform’ ahead of AVANZAR lung cancer trial
RBC outperform ahead of lung cancer trial. - +7.0 GSK (LSE:GSK) Could Be 14% Below Fair Value As R and D Spending Rises
Valuation analysis suggests shares undervalued despite rising R&D spending. - +6.8 Smith & Nephew launches CARTIHEAL in Europe for Smith & Nephew stock investors - ad-hoc-news.de
European launch of CARTIHEAL product, expanding its portfolio. - +6.7 AstraZeneca PLC Stock (AZN) Moved Up by 3.55% on Oct 15: What Signal Does It Send?
Shares rose 3.55%. - +6.7 AstraZeneca Stock Analysis: Gains 3.24%, Testing Key Resistance
Share price gain, testing resistance. - +6.3 AstraZeneca and insitro Sign USD 1.5 Billion AI Drug Discovery Partnership
Large AI partnership worth up to $1.5bn. - +5.8 AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
Expands MASH and cardio work via AI partnership.
Pharma and healthcare: every day · FTSE 100 overview for the day